Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04NUZ
|
|||
Former ID |
DNC008900
|
|||
Drug Name |
C[Glu26-Lys30][Gly8]GLP-1(7-37)-NH2
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C152H227N41O47
|
|||
Canonical SMILES |
CCC(C)C1C(=O)NC(CCCCNC(=O)CCC(C(=O)NC(C(=O)NC(C(=O)N1)CC2=CC=CC=C2)CCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N
|
|||
InChI |
1S/C152H227N41O47/c1-15-78(10)123-149(238)178-94(134(223)183-105(60-86-63-162-91-34-23-22-33-89(86)91)139(228)180-101(56-75(4)5)140(229)190-121(76(6)7)147(236)177-93(35-24-26-52-153)130(219)165-67-114(204)171-92(37-28-54-161-152(157)158)129(218)163-65-111(156)201)36-25-27-53-160-112(202)48-43-98(135(224)176-99(46-51-119(211)212)136(225)181-103(141(230)192-123)57-83-29-18-16-19-30-83)174-127(216)80(12)169-126(215)79(11)170-133(222)97(42-47-110(155)200)173-115(205)68-166-132(221)96(45-50-118(209)210)175-137(226)100(55-74(2)3)179-138(227)102(59-85-38-40-88(199)41-39-85)182-144(233)107(70-194)186-146(235)109(72-196)187-148(237)122(77(8)9)191-143(232)106(62-120(213)214)184-145(234)108(71-195)188-151(240)125(82(14)198)193-142(231)104(58-84-31-20-17-21-32-84)185-150(239)124(81(13)197)189-116(206)69-167-131(220)95(44-49-117(207)208)172-113(203)66-164-128(217)90(154)61-87-64-159-73-168-87/h16-23,29-34,38-41,63-64,73-82,90,92-109,121-125,162,194-199H,15,24-28,35-37,42-62,65-72,153-154H2,1-14H3,(H2,155,200)(H2,156,201)(H,159,168)(H,160,202)(H,163,218)(H,164,217)(H,165,219)(H,166,221)(H,167,220)(H,169,215)(H,170,222)(H,171,204)(H,172,203)(H,173,205)(H,174,216)(H,175,226)(H,176,224)(H,177,236)(H,178,238)(H,179,227)(H,180,228)(H,181,225)(H,182,233)(H,183,223)(H,184,234)(H,185,239)(H,186,235)(H,187,237)(H,188,240)(H,189,206)(H,190,229)(H,191,232)(H,192,230)(H,193,231)(H,207,208)(H,209,210)(H,211,212)(H,213,214)(H4,157,158,161)/t78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,121-,122-,123-,124-,125-/m0/s1
|
|||
InChIKey |
JGAQRLVKKDZZTH-KXYXCEFHSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.